Illumen Therapeutics Inc.
PrivateLast Round
Pre Seed
Jan 6, 2026
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Illumen Therapeutics Inc. is a biotechnology company developing first-in-class PARN inhibitor drugs to treat aggressive cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Illumen Therapeutics Inc. Comparables
Compare Illumen Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vona Oncology | 72% | |
| p53-Therapeutics, Inc. | 66% | |
| Lamassu BioTech | 65% | |
Illumen Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Jan 6, 2026 |
Illumen Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Venture Partners at CU Boulder | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 6, 2026
Led by Venture Partners at CU Boulder.
Illumen Therapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Illumen Therapeutics Inc.'s valuation, stock price, and market status.